Logo.png
Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell
March 06, 2024 08:30 ET | Hepion Pharmaceuticals, Inc.
EDISON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on therapeutic drug development for the treatment of...
Research Nester Logo.jpg
Non-Alcoholic Steatohepatitis Treatment Market revenue to reach USD 48.3 Billion by 2035, says Research Nester
March 06, 2024 06:00 ET | Research Nester
New York , March 06, 2024 (GLOBE NEWSWIRE) -- The global non-alcoholic steatohepatitis treatment market size is predicted to expand at 18% CAGR between 2023 and 2035. The market is projected to...
Organovo Logo (2 Color Med-Res-082117).png
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
December 06, 2023 08:05 ET | Organovo, Inc.
SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and...
TIP_link_300x300.jpg
Non-Alcoholic Steatohepatitis (NASH) Market Worth $24.26Bn, Globally, by 2028 at 47.1% CAGR - Exclusive Report by The Insight Partners
May 04, 2022 08:37 ET | The Insight Partners
New York, May 04, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Non-Alcoholic Steatohepatitis (NASH) Market Forecast to 2028 - COVID-19 Impact and Global Analysis...
Vantage Market Research.png
NASH (Non-Alcoholic Steatohepatitis) Market to Reach USD 21,879 Million by 2028 - Powered by Increasing Pharmaceutical R&D Expenditure and Escalating Obese Population- Vantage Market Research
February 09, 2022 05:06 ET | Vantage Market Research
WASHINGTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research’s recent analysis of the Global Non-Alcoholic Steatohepatitis (NASH) Market finds that growing demand for ideal NASH...
logo.png
Adhera Therapeutics Announces Uplisting to OTCQB Venture Marketplace
January 20, 2022 08:45 ET | Adhera Therapeutics, Inc.
Baton Rouge, LA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce its...
FibroNest Liver NASH Biopsy Quantitative Image Analysis
PharmaNest Announces New Pre-Clinical and Clinical NASH Data to Be Presented at the AASLD - The Liver Meeting Digital Experience™ (TLMdX) 2021
November 12, 2021 08:00 ET | PHARMANEST
PRINCETON, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- PharmaNest is a digital pathology and artificial intelligence company that is focused on the development and validation of novel standards for...
Metacrine-Logo-R Transparent.png.png
Metacrine Achieves Full Enrollment for MET642 Phase 2a Trial in Patients With Nash
September 09, 2021 08:05 ET | Metacrine, Inc.
Exceeded enrollment target of 180 total patientsInterim data from the first 60 patients expected early in the fourth quarter of 2021Topline MET642 trial results from all patients are anticipated in...
Metacrine-Logo-R Transparent.png.png
Metacrine to Host Virtual R&D Day for Analysts and Investors on September 15, 2021
September 08, 2021 08:05 ET | Metacrine, Inc.
Featuring KOL and management discussions on the science of FXR agonists and the Company’s programs in NASH and IBD SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a...
Metacrine-Logo-R Transparent.png.png
Metacrine to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 08:05 ET | Metacrine, Inc.
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and...